Tirilazad mesylate protects stored erythrocytes against osmotic fragility.
The hypoosmotic lysis curve of freshly collected human erythrocytes is consistent with a single Gaussian error function with a mean of 46.5 +/- 0.25 mM NaCl and a standard deviation of 5.0 +/- 0.4 mM NaCl. After extended storage of RBCs under standard blood bank conditions the lysis curve conforms to the sum of two error functions instead of a possible shift in the mean and a broadening of a single error function. Thus, two distinct sub-populations with different fragilities are present instead of a single, broadly distributed population. One population is identical to the freshly collected erythrocytes, whereas the other population consists of osmotically fragile cells. The rate of generation of the new, osmotically fragile, population of cells was used to probe the hypothesis that lipid peroxidation is responsible for the induction of membrane fragility. If it is so, then the antioxidant, tirilazad mesylate (U-74,006f), should protect against this degradation of stored erythrocytes. We found that tirilazad mesylate, at 17 microM (1.5 mol% with respect to membrane lecithin), retards significantly the formation of the osmotically fragile RBCs. Concomitantly, the concentration of free hemoglobin which accumulates during storage is markedly reduced by the drug. Since the presence of the drug also decreases the amount of F2-isoprostanes formed during the storage period, an antioxidant mechanism must be operative. These results demonstrate that tirilazad mesylate significantly decreases the number of fragile erythrocytes formed during storage in the blood bank.
Physical and Analytical Chemistry, Upjohn Laboratories, Kalamazoo, MI 49001.
D E
DE
Epps
T J
TJ
Knechtel
O
O
Bacznskyj
D
D
Decker
D M
DM
Guido
S E
SE
Buxser
W R
WR
Mathews
S L
SL
Buffenbarger
B S
BS
Lutzke
J M
JM
McCall
D000975:Antioxidants; D001793:Blood Preservation / Q000379:methods*; D015237:Dinoprost / Q000378:metabolism; D004910:Erythrocyte Membrane / Q000187:drug effects; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D009996:Osmotic Fragility / Q000187:drug effects*; D011281:Pregnatrienes / Q000494:pharmacology*; D013997:Time Factors; D014810:Vitamin E / Q000097:blood
D000975:Antioxidants; D011281:Pregnatrienes; D014810:Vitamin E; D015237:Dinoprost; C053355:tirilazad